| abstract |
The present invention relates to the use of VEGF antagonists in the treatment of retinal neovascularization disorders in infants. In particular, the invention provides a method of treating an infant with ROP, wherein the method comprises administering a VEGF antagonist that does not enter the systemic circulation in the infant ' s eyes or is quickly cleared from the systemic circulation. The term "infant" is typically used to refer to young children from birth to 12 months of age. VEGF antagonists can be administered, for example, by injection into the vitreous body, or topically, for example, in the form of eye drops. |